What Jiangsu NHWA Pharmaceutical does

Jiangsu NHWA Pharmaceutical is a China-based specialty pharmaceutical company founded in 1978 and listed on the Shenzhen Stock Exchange (002262.sz) since 2008, headquartered in Xuzhou, Jiangsu. It is one of the few Chinese pharmaceutical manufacturers focused almost exclusively on central nervous system (CNS) therapeutics, spanning anesthetics, psychiatric drugs, and neurological agents. The company operates a national-level psychotropic drug designated production base of more than 900 acres, holds GMP, EU CEP, and Japan PMDA certifications, and exports products to over 50 countries. It runs a national-level enterprise technical center and a postdoctoral research workstation, and has assembled a specialty CNS pipeline through a combination of internal R&D and in-licensing deals with global partners including Teva (AUSTEDO), Trevena (Oliceridine/TRV130, approved by NMPA in May 2023), Lundbeck (NHL35700 in Phase III), and Luye Pharma (three long-acting injectable antipsychotics, partnership signed late 2025).

The company's revenue model combines domestic generic and specialty CNS drug sales with export income. Domestically, it sells through 166 sales offices covering 29 provinces and reaches more than 22,000 hospitals and 21,000 retail pharmacies; in April 2026 it signed a strategic cooperation with Shanghai Pharmaceuticals Holding to extend nationwide controlled-drug distribution. Internationally, products are exported to more than 50 countries leveraging EU and Japan regulatory certifications. Product launches in 2025 — hydrocodone, tapentadol, and vortioxetine tablets — mark an explicit shift up the value chain from legacy generics toward differentiated analgesics and antidepressants.

NHWA serves institutional healthcare buyers (hospitals, psychiatric and neurological clinics), retail pharmacies, and international distributors; its CNS specialization, controlled-substance regulatory licenses, and 47-year operating history constitute the core of its competitive position. The customer base is broad and fragmented rather than concentrated, with policy and reimbursement risk (CNS drug reimbursement in particular) acting as the primary macroeconomic exposure.

Name

Jiangsu NHWA Pharmaceutical

Legal name

江苏恩华药业股份有限公司

Website

https://nhwa-group.com

Company type

Public

Founded year

1978

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Jiangsu NHWA Pharmaceutical is a Xuzhou-based, Shenzhen-listed specialty pharmaceutical company focused on central nervous system drugs — anesthetics, psychiatric, and neurological agents — selling to hospitals, pharmacies, and export markets across 50+ countries.

Ownership category

akta.pro rank

Product category

Central Nervous System Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Small-Molecule API Commercial Manufacturing (HLAGAHAB), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Central nervous system drugs
• Active pharmaceutical ingredients
• Anesthetic medications
• Psychiatric pharmaceutical products
• Finished dosage formulations

Headquarters

HQ city

Xuzhou

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Manufacturing and Sales: 主要生产经营中枢神经系统用药，包括麻醉类、精神类和神经类药物。拥有原料药和制剂药物三个大型现代化医药生产基地，总占地面积900余亩。原料药46种600吨/年；西药制剂110余种，固体制剂60亿片（粒）/年、针剂2亿支/年的生产规模。

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Jiangsu NHWA Pharmaceutical manufactures and sells central nervous system (CNS) drugs spanning anesthesia, psychiatric, and neurological therapeutic areas. The company operates three large-scale GMP-certified production bases producing over 40 active pharmaceutical ingredients (APIs) and 110+ finished dosage forms including tablets, capsules, injections, and lyophilized preparations. Its portfolio also includes Class 1 innovative drugs and generic products distributed through a national sales network of 166 offices and exported to more than 50 countries.

Product overview

Jiangsu NHWA Pharmaceutical is a fully integrated pharmaceutical company specializing in the central nervous system (CNS) drug sector. The company operates a comprehensive portfolio consisting of: (1) Active Pharmaceutical Ingredients (APIs) - over 40 CNS, anesthetic/sedative, and anti-fungal APIs; (2) Finished dosage forms - tablets, capsules, and injectable products across anesthesia, psychiatry, and neurology categories; (3) Key products include Class 1 innovative drugs NHL35700 (antipsychotic from Lundbeck partnership) and Oliceridine Injection TRV130 (G-protein biased opioid agonist); (4) Generics including Deutetrabenazine tablets and various CNS medications; (5) Domestic marketing network with 166 offices and international export operations covering 50+ countries. R&D capabilities are concentrated in Suzhou Nhwa Biomedical and Shanghai Shujing Biotechnology subsidiaries, with a provincial key laboratory focused on CNS drug development.

Differentiator

Problem solved

Functional benefit

Products and services

• Central Nervous System APIs

Quantifiable outcome

• 覆盖22000家综合及精神专科病院
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

15 partnerships are on record, tiered core and minor.

• Shanghai Pharma Holding (上药控股)coreChannel Partner/ Reseller/ Distributor · 1 April 2026April 2026 strategic cooperation in special drugs field. Building on 2025 collaboration in psychotropic drugs, Shanghai Pharma will leverage its national integrated supply chain to help Nhwa's core products reach more patients nationwide.
• Green Valley Pharmaceutical (绿叶制药)coreStrategic or Co-development Partner · 1 December 2025December 2024 strategic cooperation where Nhwa obtained exclusive commercialization rights for three long-acting injectable antipsychotic products (Recaptus/Rispade/others) in mainland China. Green Valley continues to hold asset rights and is responsible for production.
• Teva Pharmaceutical Industries (梯瓦制药)coreChannel Partner/ Reseller/ Distributor · 1 February 2024In February 2024, Teva Pharmaceutical Industries partnered with Jiangsu Nhwa Pharmaceutical to distribute AUSTEDO (deutetrabenazine) in China, leveraging Nhwa's neuropsychiatric market presence. Teva subsequently received FDA approval in May 2024 for AUSTEDO XR tablets.
• Teva Pharmaceutical Industries (梯瓦制药)coreStrategic or Co-development Partner · 1 February 2024February 2024 strategic cooperation for distribution of AUSTEDO products in China, leveraging Jiangsu Nhwa's neuropsychiatric market presence and established sales network.
• H. Lundbeck A/S (丹麦灵北)coreOEM/ Whitelabel/ Licensing Partner · 1 November 2021Exclusive license agreement signed November 2021 for NHL35700 (Lu AF35700) development, manufacturing and commercialization rights in Greater China. Lundbeck retains ownership and provides ongoing support. Phase III clinical trial initiated in China.
• Complix NV (比利时)minorOEM/ Whitelabel/ Licensing Partner · 1 July 2021Drug development and licensing agreement for undisclosed therapeutic candidate.
• The Brigham and Women's Hospital, Inc. and Biodextris Inc.minorStrategic or Co-development Partner · 1 April 2019Exclusive technology license agreement for Protollin development - a novel immunostimulatory therapy for neurological diseases.
• Trevena Inc. (美国)coreOEM/ Whitelabel/ Licensing Partner · 1 April 2018Exclusive license for TRV130 (oliceridine injection) development and commercialization in China. Product approved by NMPA in May 2023 as first biased mu-opioid receptor agonist.
• Jiangsu Jingliang Pharmaceutical Technology (江苏晶立信)minorStrategic or Co-development Partner · 1 April 2018Collaboration on paliperidone palmitate long-acting injection development.
• Zysis Ltd. (英国)minorOEM/ Whitelabel/ Licensing Partner · 1 March 2017License agreement for aripiprazole long-acting formulation.
• NuvOx Pharma, LLC (美国)minorOEM/ Whitelabel/ Licensing Partner · 1 January 2017License agreement for NVX-408 therapeutic product.
• Mapi Pharma Ltd. (以色列)minorStrategic or Co-development Partner · 1 September 2016Equity subscription and partnership for product development.
• Liebel-Flarsheim Company (美国立博)minorOEM/ Whitelabel/ Licensing Partner · 1 June 2016Exclusive license and cooperation agreement for propofol injection.
• Xuzhou Red Cross Society (徐州市红十字会)minorOthersCharitable donation recipient for COVID-19 prevention supplies.
• Xuzhou Civil Affairs Bureau (徐州市民政局)minorOthersCharitable donations recipient for Henan flood relief.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• H. Lundbeck A/S: Lundbeck is a global CNS specialty pharmaceutical company focused exclusively on psychiatric and neurological disorders. NHWA's exclusive Greater China partner for NHL35700. Comparable as a CNS-only global pharma, though larger than NHWA.
• Sino Biopharmaceutical: Sino Biopharm is a major Hong Kong-listed Chinese pharmaceutical conglomerate with diverse therapeutic interests including CNS, oncology, and cardiovascular. Comparable as a large diversified Chinese pharma with significant CNS exposure.
• Jiangsu Hengrui Pharmaceuticals: Hengrui is China's largest innovative pharmaceutical company with broad therapeutic coverage including oncology, anesthesia, and CNS treatments. Comparable as a Chinese listed pharma incumbent, though at much larger scale and more diversified across multiple therapeutic areas.
• Teva Pharmaceutical Industries: Teva is one of the world's largest generic pharmaceutical companies with a substantial CNS franchise (Austedo, Ajovy, Austedo XR). NHWA is Teva's distribution partner for AUSTEDO in China. Comparable for CNS portfolio breadth and generic+specialty mix.

Direct peers

• CSPC Pharmaceutical Group: CSPC is a major Chinese pharmaceutical company with a significant CNS franchise (including blockbuster butylphthalide/NBP for stroke) and substantial finished-dose and API capabilities. Comparable for Chinese CNS-focused pharma with innovation pipeline.
• Luye Pharma Group: Luye Pharma is a leading Chinese CNS-focused pharmaceutical company with strong positions in oncology and CNS. Most directly comparable as a CNS specialist—and now NHWA's commercialization partner for three long-acting injectable antipsychotics in China.
• Hansoh Pharmaceutical Group: Hansoh is a leading Chinese specialty pharmaceutical company with a strong CNS/franchise, including oncology, psychiatry, and infectious disease products. Comparable as a Chinese innovator specialty pharma with both branded and generic operations.

Emerging players

• Zai Lab: Zai Lab is a China-based innovative biopharmaceutical company focused on oncology, autoimmune, and CNS—leveraging in-licensed assets from global partners. Comparable as a Chinese innovation-focused pharma with CNS exposure and a licensing-driven model.
• Trevena Inc. Trevena is a US-based CNS-focused biopharmaceutical company that developed and licensed oliceridine (TRV130) to NHWA for China commercialization. Comparable as a CNS innovator partnering with larger pharma for distribution.

Regional players

• Shanghai Pharmaceuticals Holding: Shanghai Pharma is a leading Chinese state-owned pharmaceutical distribution and manufacturing company. NHWA's strategic distribution partner for nationwide supply chain. Comparable as a Chinese pharma with both manufacturing and distribution capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance17 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jiangsu NHWA Pharmaceutical